| Year |
Citation |
Score |
| 2017 |
Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE. High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Medicine. PMID 28994212 DOI: 10.1002/Cam4.1223 |
0.359 |
|
| 2016 |
Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N. Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience. 10: 676. PMID 27729941 DOI: 10.3332/Ecancer.2016.676 |
0.346 |
|
| 2016 |
Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, et al. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunology, Immunotherapy : Cii. PMID 27277816 DOI: 10.1007/S00262-016-1854-1 |
0.334 |
|
| 2016 |
Samlowski WE, Wojcik J, Samlowski S, Fife D, Murry T. Case Report: Pazopanib Treatment Response in a Patient with Metastatic Pleomorphic Dermal Sarcoma (Atypical Fibroxanthoma) with Circulating Tumor Cell-Derived Colonies as a Predictive Marker Journal of Cancer Therapy. 7: 785-793. DOI: 10.4236/Jct.2016.711079 |
0.321 |
|
| 2015 |
Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Straubhar AM, Agarwal AM, Van Atta J, Grossmann KF, Samlowski WE, et al. Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2). Journal of Clinical Oncology. 33: 4565-4565. DOI: 10.1200/Jco.2015.33.15_Suppl.4565 |
0.394 |
|
| 2014 |
Samlowski WE, McGregor JR, Samlowski ST, Tharkar S, Shen S, Bentz JS. Growth of Circulating Tumor Cell-Derived Colonies from Peripheral Blood of Melanoma Patients: Preliminary Characterization of Colony Composition Health. 6: 1467-1481. DOI: 10.4236/Health.2014.612181 |
0.305 |
|
| 2014 |
Batten JA, Samlowski WE, Parikh K, Sendilnathan A, Crispin H, Van Atta J, Sageser D, Grossmann KF, Wang J, Tantravahi SK, Stenehjem DD, Agarwal N. Association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2). Journal of Clinical Oncology. 32: 487-487. DOI: 10.1200/Jco.2014.32.4_Suppl.487 |
0.459 |
|
| 2014 |
Stenehjem DD, Parikh K, Batten JA, Van Atta J, Crispin H, Sageser DS, Grossmann KF, Wang J, Tantravahi SK, Samlowski WE, Agarwal N. Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Journal of Clinical Oncology. 32: 476-476. DOI: 10.1200/Jco.2014.32.4_Suppl.476 |
0.427 |
|
| 2014 |
Agarwal N, Parikh K, Tantravahi SK, Crispin H, Van Atta J, Batten JA, Sageser D, Samlowski WE, Grossmann KF, Wang J, Stenehjem DD. Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 32: 461-461. DOI: 10.1200/Jco.2014.32.4_Suppl.461 |
0.407 |
|
| 2014 |
Parikh K, Stenehjem DD, Sendilnathan A, Crispin H, Van Atta J, Batten JA, Sageser D, Grossmann KF, Wang J, Samlowski WE, Tantravahi SK, Agarwal N. Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2). Journal of Clinical Oncology. 32: 460-460. DOI: 10.1200/Jco.2014.32.4_Suppl.460 |
0.431 |
|
| 2014 |
Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal AM, Sendilnathan A, Van Atta J, Batten JA, Grossmann KF, Samlowski WE, Stenehjem DD, Agarwal N. Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2). Journal of Clinical Oncology. 32: 4577-4577. DOI: 10.1200/Jco.2014.32.15_Suppl.4577 |
0.391 |
|
| 2013 |
Donepudi S, Reisinger SA, McGregor JR, Tharkar S, Samlowski S, Ostler D, Shen S, Samlowski WE. Circulating Tumor Cell Cultures as a Predictive Marker during Salvage Therapy of Refractory Merkel Cell Carcinoma with Chemotherapy and Electron Beam Radiation Journal of Cancer Therapy. 4: 1162-1166. DOI: 10.4236/Jct.2013.47135 |
0.332 |
|
| 2012 |
Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer. 118: 6055-62. PMID 22674198 DOI: 10.1002/Cncr.27668 |
0.314 |
|
| 2012 |
Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE. CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma. Journal of Clinical Oncology. 30: 8527-8527. DOI: 10.1200/Jco.2012.30.15_Suppl.8527 |
0.354 |
|
| 2012 |
McGregor JR, Samlowski WE, Tharkar S, Donepudi S, Ferrone S. Isolation and expansion of circulating tumor cells (CTC) from melanoma patients using a novel cell culture technique. Journal of Clinical Oncology. 30: 10614-10614. DOI: 10.1200/Jco.2012.30.15_Suppl.10614 |
0.306 |
|
| 2011 |
Fruehauf JP, Eroglu Z, Kong KM, Jakowatz JG, Akerley WL, Samlowski WE. A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8546. PMID 28021085 DOI: 10.1200/Jco.2011.29.15_Suppl.8546 |
0.329 |
|
| 2011 |
Heller KN, Pavlick AC, Hodi FS, Thompson JA, Margolin KA, Lawrence DP, McDermott DF, Samlowski WE, Michener T, Karasarides M. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8581. PMID 28020986 DOI: 10.1200/Jco.2011.29.15_Suppl.8581 |
0.345 |
|
| 2011 |
Shapiro DG, Samlowski WE. Management of melanoma brain metastases in the era of targeted therapy. Journal of Skin Cancer. 2011: 845863. PMID 22220282 DOI: 10.1155/2011/845863 |
0.37 |
|
| 2011 |
Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP. Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemotherapy and Pharmacology. 68: 1081-7. PMID 21769667 DOI: 10.1007/S00280-011-1703-Z |
0.325 |
|
| 2011 |
Samlowski WE, Kondapaneni M, Tharkar S, McGregor JR, Laubach VE, Salvemini D. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 419-27. PMID 21577143 DOI: 10.1097/Cji.0B013E31821Dcb50 |
0.757 |
|
| 2011 |
Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Investigational New Drugs. 29: 489-98. PMID 20082117 DOI: 10.1007/S10637-009-9376-8 |
0.301 |
|
| 2010 |
Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 116: 3683-91. PMID 20564083 DOI: 10.1002/Cncr.25119 |
0.309 |
|
| 2010 |
Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 116: 155-63. PMID 19877111 DOI: 10.1002/Cncr.24720 |
0.313 |
|
| 2010 |
Samlowski WE, McGregor J, Buys SS, Ward JH, Gregovich G, Witter M, Petersen FB. Phase I evaluation of an 18-day outpatient IL-2 infusion following AC+t adjuvant chemotherapy of loco-regionally advanced breast cancer (BrCA). Journal of Clinical Oncology. 28: e11051-e11051. DOI: 10.1200/Jco.2010.28.15_Suppl.E11051 |
0.359 |
|
| 2009 |
Vogelzang NJ, Hutson TE, Samlowski W, Somer B, Richey S, Alemany C, Loesch D, Richards P, Gardner L, Sportelli P. Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5034. PMID 27962937 DOI: 10.1200/Jco.2009.27.15_Suppl.5034 |
0.309 |
|
| 2009 |
Irwan YY, Feng Y, Gach HM, Symanowski JT, McGregor JR, Veni G, Schabel M, Samlowski WE. Quantitative analysis of cytokine-induced vascular toxicity and vascular leak in the mouse brain. Journal of Immunological Methods. 349: 45-55. PMID 19665029 DOI: 10.1016/J.Jim.2009.07.014 |
0.617 |
|
| 2009 |
Chan F, Samlowski EE, Samlowski WE. Temsirolimus: A Review of its Use in the Treatment of Advanced Renal Cell Carcinoma Clinical Medicine. Therapeutics. 1: CMT.S2349. DOI: 10.4137/Cmt.S2349 |
0.336 |
|
| 2008 |
Hersh EM, Weber JS, Powderly JD, Khan K, Pavlick AC, Samlowski WE, O'Day SJ, Nichol G, Yellin MJ, Cramner L. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 9022. PMID 27950719 DOI: 10.1200/Jco.2008.26.15_Suppl.9022 |
0.306 |
|
| 2008 |
Samlowski WE, Vogelzang NJ. Conclusion and future directions. Cancer Journal (Sudbury, Mass.). 14: 330-2. PMID 18836339 DOI: 10.1097/Ppo.0B013E3181867617 |
0.303 |
|
| 2008 |
Samlowski WE, Majer M, Boucher KM, Shrieve AF, Dechet C, Jensen RL, Shrieve DC. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer. 113: 2539-48. PMID 18780316 DOI: 10.1002/Cncr.23857 |
0.37 |
|
| 2008 |
Samlowski WE, Wong B, Vogelzang NJ. Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on. Bju International. 102: 162-5. PMID 18410430 DOI: 10.1111/J.1464-410X.2008.07670.X |
0.31 |
|
| 2008 |
Kondapaneni M, McGregor JR, Salvemini D, Laubach VE, Samlowski WE. Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 325-33. PMID 18391763 DOI: 10.1097/Cji.0B013E31816112E8 |
0.754 |
|
| 2008 |
Powderly JD, O’Day SJ, Hersh EM, Tchekmedyian S, Hodi FS, Nichol G, Yellin MJ, Urba WJ, Samlowski WE, Weber JS. Prolonged survival in objective responders to ipilimumab therapy Journal of Clinical Oncology. 26: 20004-20004. DOI: 10.1200/Jco.2008.26.15_Suppl.20004 |
0.331 |
|
| 2007 |
Samlowski WE, Jensen RL, Shrieve DC. Multimodality management of brain metastases in metastatic melanoma patients. Expert Review of Anticancer Therapy. 7: 1699-705. PMID 18062744 DOI: 10.1586/14737140.7.12.1699 |
0.379 |
|
| 2007 |
Samlowski WE, Vogelzang NJ. Emerging drugs for the treatment of metastatic renal cancer. Expert Opinion On Emerging Drugs. 12: 605-18. PMID 17979602 DOI: 10.1517/14728214.12.4.605 |
0.345 |
|
| 2007 |
Majer M, Samlowski WE. Management of metastatic melanoma patients with brain metastases. Current Oncology Reports. 9: 411-6. PMID 17706170 DOI: 10.1007/S11912-007-0056-6 |
0.363 |
|
| 2007 |
Majer M, Jensen RL, Shrieve DC, Watson GA, Wang M, Leachman SA, Boucher KM, Samlowski WE. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer. 110: 1329-37. PMID 17623835 DOI: 10.1002/Cncr.22905 |
0.366 |
|
| 2007 |
Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Investigation. 25: 182-8. PMID 17530488 DOI: 10.1080/07357900701209061 |
0.318 |
|
| 2007 |
Samlowski WE, Watson GA, Wang M, Rao G, Klimo P, Boucher K, Shrieve DC, Jensen RL. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer. 109: 1855-62. PMID 17351953 DOI: 10.1002/Cncr.22605 |
0.355 |
|
| 2007 |
Vukelja SJ, Anthony SP, Arseneau JC, Berman BS, Cunningham CC, Nemunaitis JJ, Samlowski WE, Fowers KD. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anti-Cancer Drugs. 18: 283-9. PMID 17264760 DOI: 10.1097/Cad.0B013E328011A51D |
0.303 |
|
| 2007 |
Gonzalez R, Lewis K, Samlowski W, Cranmer L, Catlett J, Kirkwood J, Whitman E, Lawson D, Bartels P, Drake T. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma Journal of Clinical Oncology. 25: 8538-8538. DOI: 10.1200/Jco.2007.25.18_Suppl.8538 |
0.319 |
|
| 2007 |
Pan C, Hussey M, Lara P, Mack PC, Nagle RB, Dutcher J, Samlowski W, Clark J, Crawford ED, Gordon MS. Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC)—SWOG S0317 Journal of Clinical Oncology. 25: 15516-15516. DOI: 10.1200/Jco.2007.25.18_Suppl.15516 |
0.307 |
|
| 2006 |
Samlowski WE, McGregor JR, Jurek M, Baudys M, Zentner GM, Fowers KD. ReGel polymer-based delivery of interleukin-2 as a cancer treatment. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 524-35. PMID 16971808 DOI: 10.1097/01.Cji.0000211306.05869.25 |
0.436 |
|
| 2006 |
Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer. 107: 319-27. PMID 16779801 DOI: 10.1002/Cncr.21994 |
0.308 |
|
| 2006 |
Rao G, Klimo P, Thompson CJ, Samlowski W, Wang M, Watson G, Shrieve D, Jensen RL. Stereotactic radiosurgery as therapy for melanoma, renal carcinoma, and sarcoma brain metastases: Impact of added surgical resection and whole-brain radiotherapy International Journal of Radiation Oncology*Biology*Physics. 66: S20-S25. DOI: 10.1016/J.Ijrobp.2006.05.078 |
0.357 |
|
| 2005 |
Fischkoff SA, Hersh E, Weber J, Powderly J, Khan K, Pavlick A, Samlowski W, O'Day S, Nichol G, Yellin M. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7525. PMID 27946225 DOI: 10.1200/Jco.2005.23.16_Suppl.7525 |
0.327 |
|
| 2004 |
Worden FP, Moon J, Samlowski W, Clark J, Dakhil SR, Taylor SA, Urba SG, Hussain M. A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head & neck (SCCHN): A Southwest Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 5512. PMID 28014177 DOI: 10.1200/Jco.2004.22.14_Suppl.5512 |
0.311 |
|
| 2004 |
Stiff PJ, Shpall EJ, Liu PY, Wilczynski SP, Callander NS, Scudder SA, Jazieh AR, Samlowski W, McCoy J, Alberts DS. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecologic Oncology. 94: 98-106. PMID 15262126 DOI: 10.1016/J.Ygyno.2004.02.032 |
0.316 |
|
| 2004 |
Kwon OD, Yim CY, Jeong KS, Park SC, Jung KY, McGregor JR, Bastian NR, Samlowski WE. Suppression of cytokine-inducible nitric oxide synthesis during intraperitoneal Meth A tumor growth. The Journal of Veterinary Medical Science / the Japanese Society of Veterinary Science. 66: 357-65. PMID 15198099 DOI: 10.1292/Jvms.66.357 |
0.332 |
|
| 2004 |
Whitehead RP, Benedetti JK, Abbruzzese JL, Ardalan B, Goodwin JW, Balcerzak SP, Samlowski WE, Lenz HJ, Macdonald JS. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study. Investigational New Drugs. 22: 335-41. PMID 15122082 DOI: 10.1023/B:Drug.0000026261.76197.54 |
0.335 |
|
| 2003 |
Samlowski WE, Petersen R, Cuzzocrea S, Macarthur H, Burton D, McGregor JR, Salvemini D. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nature Medicine. 9: 750-5. PMID 12730689 DOI: 10.1038/Nm874 |
0.446 |
|
| 2001 |
Samlowski WE, Gundacker H, Kuebler JP, Giguere JK, Mills GM, Schuller DE, Ensley JF. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Southwest Oncology Group Phase II study Investigational New Drugs. 19: 311-315. PMID 11561690 DOI: 10.1023/A:1010657609609 |
0.333 |
|
| 2001 |
Whitehead RP, Unger JM, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Investigational New Drugs. 19: 239-43. PMID 11561681 DOI: 10.1023/A:1010624702340 |
0.318 |
|
| 2000 |
Kwak JY, Han MK, Choi KS, Park IH, Park SY, Sohn MH, Kim UH, McGregor JR, Samlowski WE, Yim CY. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cellular Immunology. 203: 84-94. PMID 11006006 DOI: 10.1006/Cimm.2000.1682 |
0.334 |
|
| 2000 |
Schlegel PJ, Samlowski WE, Ward JH. Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia and renal cell carcinoma after treatment with high-dose intravenous bolus interleukin-2. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 507-8. PMID 10916762 DOI: 10.1097/00002371-200007000-00016 |
0.314 |
|
| 1999 |
Meyers FJ, Lew D, Lara PN, Williamson S, Marshall E, Balcerzak SP, Rivkin SE, Samlowski W, Crawford ED. Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124). Investigational New Drugs. 16: 347-51. PMID 10426670 DOI: 10.1023/A:1006128024879 |
0.346 |
|
| 1999 |
Samlowski WE, Lew D, Kuebler PJ, Kolodziej MA, Medina JE, Mangan KF, Moore DF, Schuller DE, Ensley JF. Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. Investigational New Drugs. 16: 271-4. PMID 10360608 DOI: 10.1023/A:1006178808095 |
0.333 |
|
| 1998 |
Samlowski WE, Yim CY, McGregor JR. Nitric oxide exposure inhibits induction of lymphokine-activated killer cells by inducing precursor apoptosis. Nitric Oxide : Biology and Chemistry. 2: 45-56. PMID 9706742 DOI: 10.1006/Niox.1998.0169 |
0.378 |
|
| 1998 |
Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 890-6. PMID 9508170 DOI: 10.1200/Jco.1998.16.3.890 |
0.331 |
|
| 1998 |
Samlowski WE, Wiebke G, McMurry M, Mori M, Ward JH. Effects of total parental nutrition (TPN) during high-dose interleukin-2 treatment for metastatic cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 65-74. PMID 9456439 DOI: 10.1097/00002371-199801000-00009 |
0.429 |
|
| 1995 |
Samlowski WE, Yim CY, McGregor JR, Kwon OD, Gonzales S, Hibbs JB. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during il-2 treatment of mice Journal of Immunotherapy. 18: 166-178. PMID 8770772 DOI: 10.1097/00002371-199510000-00004 |
0.465 |
|
| 1995 |
Meyskens FL, Kopecky KJ, Appelbaum FR, Balcerzak SP, Samlowski W, Hynes H. Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. Leukemia Research. 19: 605-12. PMID 7564470 DOI: 10.1016/0145-2126(95)00032-J |
0.301 |
|
| 1993 |
Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 13: 49-54. PMID 8435432 DOI: 10.1097/00002371-199301000-00007 |
0.321 |
|
| 1992 |
Birchfield GR, Rodgers GM, Girodias KW, Ward JH, Samlowski WE. Hypoprothrombinemia associated with interleukin-2 therapy: correction with vitamin K. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 11: 71-5. PMID 1734951 DOI: 10.1097/00002371-199201000-00009 |
0.359 |
|
| 1992 |
Meikle AW, Sousa JCCD, Dacosta N, Bishop DK, Samlowski WE. Direct and indirect effects of murine interleukin-2, gamma interferon, and tumor necrosis factor on testosterone synthesis in mouse Leydig cells. Journal of Andrology. 13: 437-443. DOI: 10.1002/J.1939-4640.1992.Tb03340.X |
0.409 |
|
| 1991 |
Samlowski WE, Robertson BA, Draper BK, Prystas E, McGregor JR. Effects of supravital fluorochromes used to analyze the in vivo homing of murine lymphocytes on cellular function. Journal of Immunological Methods. 144: 101-15. PMID 1960398 DOI: 10.1016/0022-1759(91)90236-9 |
0.349 |
|
| 1991 |
Meikle AW, Cardoso de Sousa JC, Ward JH, Woodward M, Samlowski WE. Reduction of testosterone synthesis after high dose interleukin-2 therapy of metastatic cancer. The Journal of Clinical Endocrinology and Metabolism. 73: 931-5. PMID 1834690 DOI: 10.1210/Jcem-73-5-931 |
0.398 |
|
| 1990 |
Mann H, Ward JH, Samlowski WE. Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations. Radiology. 176: 191-4. PMID 2353090 DOI: 10.1148/Radiology.176.1.2353090 |
0.399 |
|
| 1990 |
Taylor SA, Fleming T, Von Hoff DD, McCracken JD, Bukowski RM, Talley RW, Natale RB, Guy JT, Samlowski WE, Costanzi JH. Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study. Investigational New Drugs. 8: 77-80. PMID 2188928 DOI: 10.1007/Bf00216928 |
0.309 |
|
| 1989 |
Wilson DE, Birchfield GR, Hejazi JS, Ward JH, Samlowski WE. Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 1573-7. PMID 2789275 DOI: 10.1200/Jco.1989.7.10.1573 |
0.321 |
|
| 1986 |
Chung HT, Samlowski WE, Daynes RA. Modification of the murine immune system by glucocorticosteroids: Alterations of the tissue localization properties of circulating lymphocytes Cellular Immunology. 101: 571-585. PMID 3757048 DOI: 10.1016/0008-8749(86)90167-X |
0.332 |
|
| 1986 |
Samlowski WE, Eyre HJ, Sause WT. Evaluation of the response of unresectable carcinoid tumors to radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 12: 301-5. PMID 3082806 DOI: 10.1016/0360-3016(86)90342-1 |
0.33 |
|
| Show low-probability matches. |